SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 30, 2018. The company is an emerging growth company incorporated in Delaware. The report details a material definitive agreement entered into on the same date regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing discloses a private placement transaction with the following specific metrics:
- Total Proceeds: $4,789,502
- Units Sold: 3,193,004 units
- Price Per Unit: $1.50
- Unit Composition: One share of Common Stock and one warrant to purchase 0.5 shares of Common Stock.
- Warrant Exercise Price: $1.75 per share
- Warrant Expiration: April 30, 2021
- Total Warrant Coverage: Approximately 1,596,506 shares of Common Stock
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, existing debt levels, or general liquidity metrics outside of the proceeds from this specific transaction.
Material Changes and Use of Proceeds
The primary material change is the issuance of unregistered equity securities to accredited investors. The Company has covenanted to use the proceeds for general corporate purposes, including growth initiatives and capital expenditures. The agreement explicitly prohibits using proceeds for:
- Repayment of debt
- Redemption or repurchase of equity securities
- Settlement of claims, actions, or proceedings against the Company
Outlook, Risks, and Contingencies
Management Commentary: The transaction was executed to raise capital for growth. The Company must maintain sufficient authorized shares to cover the issuance and ensure listing approval on its principal trading market.
Risks and Contingencies:
- Dilution Limits: Investors are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (expandable to 9.99% with notice).
- Anti-Dilution: Warrant exercise prices and share counts are subject to adjustment for dividends, stock splits, or combinations.
- Change of Control: Warrant holders have rights to receive successor consideration in the event of a fundamental transaction.
- Legal Compliance: Securities were sold under Section 4(a)(2) and Regulation D exemptions; no registration under the Securities Act of 1933 was performed.
Investor Verification Checklist
- Verify the exact number of authorized shares remaining after this issuance to ensure compliance with the listing covenant.
- Confirm the current trading price of the Common Stock relative to the $1.75 warrant exercise price to assess immediate dilution risk.
- Review the Company's most recent 10-K or 10-Q to assess actual liquidity and debt levels, as this 8-K does not provide a balance sheet.
- Check for any subsequent filings regarding the actual deployment of the $4.79 million in proceeds.